SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

Key Points

• Short interest in SOPHiA GENETICS increased by 123.8% in July, rising from 16,000 shares to 35,800 shares, with 0.1% of the company's shares currently sold short.
• Institutional investors now own 31.59% of SOPHiA GENETICS, with multiple firms like Dimensional Fund Advisors and Federated Hermes significantly increasing their stakes.
• The company's stock opened at $3.30 with a market cap of $220.08 million and a negative earnings per share trend, missing consensus estimates in its last quarterly report.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 35,800 shares, agrowthof123.8% from the June 30th total of 16,000 shares. Approximately0.1% of the shares of the stock are sold short. Based on an average daily volume of 75,000 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily volume of 75,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately0.1% of the shares of the stock are sold short.

SOPHiA GENETICS Price Performance

SOPH stock traded down $0.02 during mid-day trading on Friday, reaching $3.18. 15,475 shares of the company's stock were exchanged, compared to its average volume of 76,861. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 2.94. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $4.92. The stock's 50 day moving average is $3.23 and its 200 day moving average is $3.27. The company has a market cap of $212.00 million, a price-to-earnings ratio of -7.23 and a beta of 1.00.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.58. The company had revenue of $18.32 million during the quarter, compared to analysts' expectations of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. On average, research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after buying an additional 5,432,871 shares in the last quarter. Millennium Management LLC raised its holdings in SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company's stock valued at $2,180,000 after acquiring an additional 42,689 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its stake in SOPHiA GENETICS by 14.4% in the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock worth $847,000 after acquiring an additional 32,200 shares during the last quarter. Federated Hermes Inc. grew its holdings in SOPHiA GENETICS by 89.0% during the 1st quarter. Federated Hermes Inc. now owns 189,000 shares of the company's stock worth $627,000 after acquiring an additional 89,000 shares in the last quarter. Finally, Rathbones Group PLC acquired a new position in SOPHiA GENETICS during the 2nd quarter worth approximately $504,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.